2024 Archives - MaaT Pharma

Posters Scientific Publications

MaaT013 Pooled Fecal Microbiotherapy Improves Gastrointestinal Physiology And Controls Inflammation Which Delays GvHD In A Proof-Of-Concept Humanized Mouse Study

MaaT PharmaNovember 12, 2025

Posters Scientific Publications

MaaT034, a new co-cultured microbiome ecosystem therapy candidate, potentiates anti-PD1 mediated antitumoral activity in germ-free mice

MaaT PharmaNovember 5, 2025

Posters Scientific Publications

MaaT034, a new co-cultured microbiome ecosystem therapy candidate, safely colonizes the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and stimulates immunity

MaaT PharmaApril 4, 2025

Media Videos

Replay: KOL insights and MaaT013 Data from ASH 2024 Meeting

• December 17, 2024 – MaaT Pharma - Key Opinion Leader Discussion - ASH 2024

MaaT PharmaDecember 18, 2024

Press Releases

December 10, 2024: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH…

MaaT PharmaDecember 10, 2024

Posters Scientific Publications

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe

MaaT PharmaDecember 9, 2024

Press Releases

December 5, 2024: MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded…

MaaT PharmaDecember 5, 2024

Event

35th International Symposium on ALS/MND

• December 6-8, 2024 – International Symposium on ALS/MND

MaaT PharmaDecember 3, 2024

Event

ASH Annual Meeting and Exposition

• December 7-10, 2024 – 66th ASH Annual Meeting and Exposition

MaaT PharmaDecember 3, 2024

Press Releases

November 26, 2024: MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033…

MaaT PharmaNovember 26, 2024

1 2 3 … 6 Next

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club

Rechercher un article

Filtrer par catégorie

Filtrer par date

Search an article

Filter by category

Filter by date

MaaT013 Pooled Fecal Microbiotherapy Improves Gastrointestinal Physiology And Controls Inflammation Which Delays GvHD In A Proof-Of-Concept Humanized Mouse Study

MaaT034, a new co-cultured microbiome ecosystem therapy candidate, potentiates anti-PD1 mediated antitumoral activity in germ-free mice

MaaT034, a new co-cultured microbiome ecosystem therapy candidate, safely colonizes the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and stimulates immunity

Replay: KOL insights and MaaT013 Data from ASH 2024 Meeting

December 10, 2024: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe

December 5, 2024: MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

35th International Symposium on ALS/MND

ASH Annual Meeting and Exposition

November 26, 2024: MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

COMPANY

Ressources

Contact